ActuIA Features RebrAIn’s Innovations in Supervised AI-Driven Deep Brain Stimulation

RebrAIn Featured by ActuIA for Pioneering Supervised AI-Driven Deep Brain Stimulation Targeting

We are excited to share that RebrAIn has been featured by ActuIA for our innovative work in neurosurgical targeting for Deep Brain Stimulation (DBS).

The article highlights our supervised AI-driven solutions that significantly improve patient outcomes for those with Parkinson’s Disease and Essential Tremor. Founded by Professor Emmanuel Cuny and Dr. Nejib Zemzemi, RebrAIn is transforming the landscape of neurosurgery with our precise and effective treatments.

Read the full article, “Focus on RebrAIn, the start-up that aims to revolutionize the surgical targeting of Deep Brain Stimulation”, in French on actuia.com here.

An English translation by Google is available here.

Our latest public updates

Rebrain x Worldwide Dystonia Research Center

May 28, 2026

Partnership aims to develop next-generation data-driven models for personalized deep brain stimulation (DBS) targeting, expanding clinical applications from Parkinson’s disease and essential tremor to dystonia and severe pediatric dystonia with global scalability...

Rebrain unveils its identity: a strong vision for the future of assisted neurosurgery

May 21, 2026

At Rebrain, innovation has never been an end in itself. It has always been a means to improve the precision of neurosurgical procedures and to have a concrete impact on patients’ lives. Today, we are reaching a new stage of our development with the official launch of...

RebrAin 2025/2026: Expanding Reach, Driving Innovation

Jan 5, 2026

Transatlantic expansion RebrAIn’s focus for 2026 is expanding our reach to major neurosurgery reference centers in the US and Europe. Today, our top partner centers by volume are Duke University, University of Virginia (UVA), Pamplona and UCLA. These collaborations...

« Older Entries